Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme ...

It feels like every week there's a new reason to head out into the streets to protest. As more and more Americans hit the streets, it's important to protect yourself as much as possible before going ...

Treatment with the investigational base-editing gene therapy ristoglogene autogetemcel (risto-cel) showed promise in patients with sickle cell disease, according to an interim analysis of the phase ...

A research team from The Hong Kong University of Science and Technology (HKUST) has made a breakthrough discovery in understanding the molecular machinery of RNA silencing. The team uncovered how the ...